BioClin Therapeutics Appoints Graeme Currie, Ph.D., as Chief Operating Officer and Esteban (Steve) Abella, M.D., as Chief Medical Officer
BioClin Therapeutics, Inc. (BioClin), a privately-held clinical stage biotechnology company developing a first-in-class anti-FGFR3 (fibroblast growth factor receptor 3) monoclonal antibody to treat solid tumors, specifically metastatic bladder cancer, announced today the appointments of Graeme Currie, Ph.D., as Chief Operating Officer and Esteban (Steve) Abella, M.D., as Chief Medical Officer. This build out of the executive team follows the closing of a $30 million Series B financing announced last year.
Dr. Currie has over 25 years of drug development experience in both pharmaceutical and biotechnology companies, having held senior leadership roles at Dynavax Technologies Corp., Regeneron Pharmaceuticals, Sepracor Inc. and PDL Biopharma.
Dr. Abella has been actively involved in cancer clinical trials research for nearly 30 years, most recently at Gilead Sciences, Inc. and Amgen, Inc.
“Graeme and Steve are tremendous additions to our team,” said Stephen Lau, Chief Executive Officer of BioClin. “Their experience in building and leading organizations, combined with their extensive work in developing and commercializing products that address important patient needs will be instrumental as we enter our next phase of growth.”
“I am thrilled to join BioClin at this important time during the company’s evolution,” said Graeme Currie, Ph.D, BioClin’s Chief Operating Officer. “Developing and implementing the clinical development strategy and planning for registrational studies for B-701 for metastatic bladder cancer is our top priority. I look forward to helping advance this important therapeutic.”
“I am excited to join this team of professionals who are scientifically driven to improve treatment options for patients,” said Steve Abella, M.D., Chief Medical Officer of BioClin. “I was impressed by the team’s expertise and energy, and I look forward to taking a leadership role in shaping BioClin’s clinical development strategy as we advance B-701 in the clinic.”
Graeme Currie was most recently Vice President of Clinical Science and Operations at Dynavax Technologies Corp. Prior to that, he spent six years at Regeneron Pharmaceuticals as the Vice President of Clinical Project Management and Operations and oversaw operations for 16 molecules and multiple therapeutic areas. During his tenure, Graeme was closely associated with the development programs for Eylea® for Wet AMD and DME, Praluent® for hypercholesterolemia and Dupixent® for Atopic Dermatitis. Prior to Regeneron, Graeme was Vice President of Clinical Operations at Sepracor Inc. and at PDL Biopharma. Graeme also spent 6 years as a Director at Gilead Sciences Inc., working in Hepatitis developing Hepsera™ for Chronic Hepatitis B. Prior to Gilead, he had roles at IPSEN Biopharmaceuticals Inc. and Glaxo Wellcome. Graeme received a BSc from the University of Salford, and a Ph.D. in Oncology from Aston University.
Esteban (Steve) Abella has been actively involved in cancer clinical trials research for nearly 30 years including most recently at Gilead Sciences Inc. At Gilead, Steve was a Senior Director leading non-hodgkin’s lymphoma and leukemia efforts, as well as serving as a core member of the oncology senior leadership team. Prior to that, he served as the Executive Director at Amgen Inc., predominately responsible for the white cell franchise (Neulasta®/Neupogen®) global development efforts across clinical research and medical affairs. His clinical experiences prior to joining industry include 15 years in academic oncology, serving as Professor of Pediatric Oncology, and Medicine at the Barbara Ann Karmanos Cancer Institute, focused on stem cell transplantation and oncology clinical trials. Steve completed his fellowship and residency training at Wayne State University School of Medicine after graduating with a degree in medicine from the Universidad Central del Este. He attended the University of Pennsylvania for undergraduate studies.
About BioClin Therapeutics, Inc.
BioClin Therapeutics, Inc. is a privately-held clinical stage biotechnology company developing biologics to address medical conditions in areas of high unmet need. The company is focused on FGFR3 (fibroblast growth factor receptor 3), a driver mutation in metastatic bladder cancer and potentially other cancers. The company’s lead program, B-701, is the only targeted biologic specific for FGFR3 in clinical development. BioClin has ongoing clinical studies in metastatic bladder cancer using multiple therapeutic approaches (as B-701 monotherapy, and in combination therapies with standard-of-care chemotherapy, as well as with pembrolizumab, an immune checkpoint inhibitor).
For more information, please visit BioClin’s website: www.bioclintherapeutics.com
BioClin Therapeutics, Inc.
Chief Executive Officer
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Smiths Detection Hold Baggage Scanner Meets Highest Security Standards in EU23.3.2018 10:00 | Tiedote
The Smiths Detection HI-SCAN 10080 XCT has achieved ECAC approval as a Standard 3.1 explosives detection system for hold baggage – the highest, defined security standard in the EU. This significant advance was made possible by using a dual-view, dual-energy line scanner with high resolution 3D Computed Tomography (CT) to deliver exceptional data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180323005050/en/ Smiths Detection HI-SCAN 10080 XCT (Graphic: Business Wire) This achievement gives airports currently upgrading to Standard 3 technology, the option to increase detection levels even further to 3.1; and any standard 3 systems already installed can be easily elevated to 3.1 via a software upgrade. The detection algorithms are interchangeable on a bag by bag basis depending on the destination and associated risk level. This offers additional flexibility and productivity. “With the capability to meet detection requirements
Sofinnova Partners Leads SafeHeal’s €6 Million Series a Financing Round23.3.2018 10:00 | Tiedote
SafeHeal, an early-stage medtech company specialized in digestive surgery and focused on the development of the Colovac device, announces today that it has closed a €6 million Series A financing round led by Sofinnova Partners. Based in Paris, SafeHeal develops an innovative digestive anastomosis protection device, called Colovac, designed to reduce complications and obviate the need for ostomies for colectomy patients. This technology consists of a minimally invasive and fully reversible implant that remains in place until the body’s natural healing and tissue repair processes are complete, for approximately two weeks, after which it is removed. SafeHeal’s device has the potential to radically transform the market while significantly improve patients’ quality of life by enabling them to resume their normal life without having to bear an artificial anus and wear ostomy pouches for several months. About 270,000 colectomy patients receive an ostomy every year in Europe and the USA, repre
Elliott Advisors (UK) Limited Statement on Telecom Italia23.3.2018 10:00 | Tiedote
Given the momentum behind Elliott's campaign at Telecom Italia to improve both performance and governance, Elliott was not surprised to see yesterday's resignation of seven board members affiliated with Vivendi. Unable to advance any meritorious arguments, the Board has simply abandoned their posts to stall for time. Elliott regards this action as cynical and self-serving, in that it delays the ability of Telecom Italia shareholders to express their votes at the upcoming AGM. This is yet another example of minority shareholder rights at Telecom Italia being abrogated and the continued disregard of corporate governance best practice. Finally, Vivendi should note Elliott's forty-year track record of consistent value creation, and sustained, long-term commitments to expose poor governance and catalyse positive change; Elliott's investment history in Telecom Italia dates back to 1999, well before Vivendi became a shareholder in the Company. About Elliott Elliott Management Corporation mana
Ipsen Receives Positive CHMP Opinion for Cabometyx® (cabozantinib) for the First-Line Treatment of Adults with Intermediate- or Poor- Risk Advanced Renal Cell Carcinoma23.3.2018 09:00 | Tiedote
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA) provided a positive opinion for Cabometyx® (cabozantinib) 20, 40, 60 mg for the first-line treatment of adults with intermediate- or poor- risk advanced renal cell carcinoma (aRCC).The CHMP positive opinion will now be reviewed by the European Commission (EC), which has the authority to approve medicines for the European Union (EU). Alexandre Lebeaut, Executive Vice President, R&D and Chief Scientific Officer said: “Today’s positive opinion from the CHMP is important news for patients with previously untreated advanced renal cell carcinoma, who can shortly benefit from Cabometyx ® as a new first-line treatment option. Following the evidence of its clinical value after a prior VEGF-targeted treatment, we are pleased to be able to expand the benefit of Cabometyx ® for treatment-naïve patients wit
Swiss Wearable Brand MyKronoz Breaks Worldwide Records with its Hybrid Smartwatch ZeTime, on the Sidelines of a Challenging Baselworld 201822.3.2018 19:32 | Tiedote
On the sidelines of a downsized Baselworld 2018, MyKronoz, the premier watchmaking brand of the smart generation today announces record-breaking crowdfunding results of its hybrid smartwatch ZeTime, with more than $8,000,000 raised in less than a year. The international success of its unique and groundbreaking flagship wearable is followed by the release of a new digital video campaign “I’m a watch; I’m a smartwatch”. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180322005963/en/ MyKronoz ZeTime Petite & Regular top $8M in crowdfunding (Photo: Business Wire) After a historic 35-days Kickstarter campaign launched in March 2017, ZeTime has pursued, since then, its crowdfunding journey on a variety of international and local platforms: Indiegogo, Makuake in Japan, Zec Zec in Taïwan, Wadiz in Korea and on the leading chinese e-commerce website JD.com. Further to this online momentum, MyKronoz has successfully shipped to over 10
Redwood Software Announces First Industry Robotic Licensing Model to Revolutionize Transparent Marketplace Pricing22.3.2018 17:59 | Tiedote
Redwood Software, the pioneer behind ‘The Robotic Enterprise’, today announced the launch of a revolutionary new robotic licensing model, where customers only pay for the robotic services they consume within their business. Available now, this new licensing model allows customers to directly compare the costs of manual work against processes that are robotized. With the unique Robotic Service Charge, Redwood only charges for the delivery of a robotic service, equivalent to a unit of work that can done by a person (send an email, download a report, reconcile two reports etc.). Redwood delivers a catalogue of 35,000 of these ready built robotic services that can be linked together by business users in a visual plug and play interface. End-to-end business processes can be modelled, robotized, tested and deployed without cost and risk. Only when the robotic service is consumed is a charge made, always replacing work that would otherwise be done manually. Within the Robotic Service Charge,
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme